High-Dose favipiravir safety trial launches in healthy volunteers
NCT ID NCT06024421
First seen Feb 20, 2026 · Last updated Jun 22, 2026 · Updated 14 times
Summary
This Phase 1 study is testing whether high doses of the antiviral drug favipiravir are safe and tolerable in healthy volunteers. About 39 participants will receive either favipiravir or a placebo for 14 days, with doses increasing in three groups. Researchers will also measure drug levels in blood and sperm, and look at genetic factors that might affect how the drug is processed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFECTIOUS DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University Hospital Bichat - Claude Bernard
RECRUITINGParis, 75018, France
Contact
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
favipiravir
What this could lead to
If successful, this could help determine safe high doses of favipiravir for future studies in infectious diseases.
What could go wrong
This is an early Phase 1 trial with only 39 healthy volunteers, so results may not apply to patients. High doses may cause side effects not yet known.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.